Clinical Trial

Phase IIT Trial of SNA014

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 17, 2024 (before its estimated October 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Trial Details
NCT Number NCT06646783
Lead Sponsor SmartNuclide Biopharma
Conditions Adenocarcinoma of the Stomach, Adenocarcinoma of GE Junction, Pancreatic Cancer Stage
Enrollment 28 participants
Start Date 2024-10-20
Primary Completion 2025-10-20 (estimated)
Study Completion 2025-11-20 (estimated)
Updated on ClinicalTrials.gov 2024-10-17